SAA levels were determined in sera from 12 healthy volunteers and 26 patients with RA ( Fig. 1) . Normal SAA concentration was 129±8 ng/ml (mean±SEM). Six patients with mildly active RA had SAA concentrations of 1883±345 ng/ml, while 13 patients with very active RA had SAA levels of 17 954±2961 ng/ml. In comparison, the SAA concentration in seven individuals with RA and secondary amyloidosis was 29 443±5907 ng/ml. (SI conversion: ng/ml=,ug/l.)
Patients with PSS had a wide range of SAA concentrations (Fig. 1) . Sixty-one (98%) of the 62 patients had elevated SAA levels. Thirty-one patients with PSS and diffuse scleroderma had a median SAA concentration of 646 ng/ml (range 284-37 800), while 31 patients with PSS and CREST syndrome had a median SAA concentration of 448 ng/ml (range 160-11 130). There was no significant difference in SAA concentration between the PSSdiffuse scleroderma and PSS-CREST syndrome groups by non-parametric statistical analysis.
For further analysis, 15 patients with moderately or markedly elevated SAA levels (1000+ ng/ml) were compared with 47 patients with normal or slightly elevated SAA concentrations (less than 1000 ng/ml) ( Table 1) . Patients with high SAA levels tended to have more extensive and severe skin thickening (diffuse scleroderma). Ten high-SAAlevel patients had PSS-diffuse and five had PSS-CREST. The patient with the highest SAA level (37 800 ng/ml) had diffuse scleroderma and renal insufficiency and subsequently died of this complication. The individual with the next highest level (18 060 ng/ml) had no evidence of visceral PSS at the time of study but died of cardiac complications six months later. The total skin score was higher in patients with high levels of SAA, and during follow-up this difference became statistically significant. There have been three deaths in the 15 patients with moderately or markedly elevated SAA compared with 4 
Discussion
In the present study all but one PSS patient had at least a mildly elevated SAA concentration. Moreover, the SAA levels in a subgroup of 15 (24%) PSS patients were in fact found to be in the same range as seen in patients with active RA. Several of the PSS patients displayed SAA concentrations similar to those observed in individuals with known amyloidosis secondary to RA. It was further noted that the subgroup of PSS patients with high levels of SAA had somewhat more severe disease at the time of initial examination, as determined by severity of skin thickening and other acute phase reactants (Table 1) . SAA production is mediated by a soluble macrophage-derived factor originally termed 'SAA inducer' and known to be closely related to interleukin 1 (IL 1).14 15 Patients with PSS have been shown to have impaired acute phase SAA responses after infusion of PGE1.8 Preliminary studies indicated that leucocytes from patients with PSS have defective IL 1 production in response to stimulation with heat killed staphylococci.8 From these observations it was postulated that patients with PSS have impaired IL 1 production in the presence of active disease, and furthermore that a presumed resultant failure to significantly increased SAA levels explains the rarity of amyloidosis in PSS. However, in another preliminary study it was found that peripheral blood mononuclear cells from a small number of patients with PSS in fact elaborated increased amounts of IL 1 activity spontaneously compared with controls. '6 Our study suggests that patients with PSS tend to have mildly elevated SAA levels, presumably as a result of low grade disease activity. With more active disease the acute phase SAA levels in PSS patients become comparable to those observed in active RA and amyloidosis secondary to RA. The rarity of amyloidosis associated with PSS does not seem to be related to an intrinsic defect in SAA production, but may be a result of the shorter duration of disease in patients with severe 
